<DOC>
	<DOC>NCT02791230</DOC>
	<brief_summary>Phase 3 extension study to evaluate the safety of oral daily dosing of 20 mg or 80 mg tafamidis meglumine in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy</brief_summary>
	<brief_title>Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy</brief_title>
	<detailed_description>Global, Phase 3, double-blind, randomized, long-term extension study to evaluate the safety of oral daily dosing of 20 mg or 80 mg tafamidis meglumine in subjects with transthyretin cardiomyopathy (TTR-CM), who have completed 30 months of study treatment on Pfizer protocol B3461028, for up to 60 months or until local access to tafamidis for TTR-CM via prescription, whichever occurs first</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Completion of 30 months of study treatment on Pfizer Protocol B3461028 Liver and/or heart transplant, or implanted cardiac mechanical assist device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>amyloidosis</keyword>
	<keyword>amyloid</keyword>
	<keyword>transthyretin</keyword>
	<keyword>TTR</keyword>
</DOC>